Steven Mah
Stock Analyst at TD Cowen
(2.20)
# 2,829
Out of 5,113 analysts
29
Total ratings
37.93%
Success rate
11.08%
Average return
Main Sectors:
Stocks Rated by Steven Mah
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TWST Twist Bioscience | Reiterates: Buy | $58 | $42.60 | +36.15% | 3 | Nov 26, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $28 → $31 | $24.98 | +24.10% | 2 | Nov 13, 2024 | |
| DNA Ginkgo Bioworks Holdings | Maintains: Outperform | $280 → $120 | $9.71 | +1,135.84% | 2 | Mar 1, 2024 | |
| RXRX Recursion Pharmaceuticals | Initiates: Market Perform | n/a | $4.60 | - | 1 | Jan 26, 2024 | |
| SDGR Schrödinger | Initiates: Outperform | $42 | $14.88 | +182.26% | 1 | Jan 26, 2024 | |
| ABCL AbCellera Biologics | Initiates: Outperform | n/a | $3.99 | - | 1 | Feb 28, 2023 | |
| OABI OmniAb | Initiates: Outperform | $10 | $1.96 | +410.20% | 1 | Feb 22, 2023 | |
| ABSI Absci | Upgrades: Outperform | n/a | $2.98 | - | 1 | Aug 12, 2022 | |
| CDXS Codexis | Maintains: Outperform | $39 → $21 | $1.43 | +1,368.53% | 2 | Jul 15, 2022 | |
| NTRA Natera | Maintains: Overweight | $150 → $155 | $240.34 | -35.51% | 4 | Jul 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $140 | $27.27 | +413.38% | 3 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $52 | $2.57 | +1,923.35% | 3 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $340 → $415 | $152.09 | +172.86% | 4 | Dec 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $168 → $250 | $27.28 | +816.42% | 1 | Jul 8, 2020 |
Twist Bioscience
Nov 26, 2024
Reiterates: Buy
Price Target: $58
Current: $42.60
Upside: +36.15%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $28 → $31
Current: $24.98
Upside: +24.10%
Ginkgo Bioworks Holdings
Mar 1, 2024
Maintains: Outperform
Price Target: $280 → $120
Current: $9.71
Upside: +1,135.84%
Recursion Pharmaceuticals
Jan 26, 2024
Initiates: Market Perform
Price Target: n/a
Current: $4.60
Upside: -
Schrödinger
Jan 26, 2024
Initiates: Outperform
Price Target: $42
Current: $14.88
Upside: +182.26%
AbCellera Biologics
Feb 28, 2023
Initiates: Outperform
Price Target: n/a
Current: $3.99
Upside: -
OmniAb
Feb 22, 2023
Initiates: Outperform
Price Target: $10
Current: $1.96
Upside: +410.20%
Absci
Aug 12, 2022
Upgrades: Outperform
Price Target: n/a
Current: $2.98
Upside: -
Codexis
Jul 15, 2022
Maintains: Outperform
Price Target: $39 → $21
Current: $1.43
Upside: +1,368.53%
Natera
Jul 6, 2021
Maintains: Overweight
Price Target: $150 → $155
Current: $240.34
Upside: -35.51%
Mar 5, 2021
Maintains: Overweight
Price Target: $135 → $140
Current: $27.27
Upside: +413.38%
Feb 11, 2021
Upgrades: Overweight
Price Target: $20 → $52
Current: $2.57
Upside: +1,923.35%
Dec 22, 2020
Upgrades: Overweight
Price Target: $340 → $415
Current: $152.09
Upside: +172.86%
Jul 8, 2020
Maintains: Overweight
Price Target: $168 → $250
Current: $27.28
Upside: +816.42%